ZNF136

gene

On this page

Also known as pHZ-20

Summary

ZNF136 (zinc finger protein 136, HGNC:12920) is a protein-coding gene on chromosome 19p13.2, encoding Zinc finger protein 136 (P52737). May be involved in transcriptional regulation as a weak repressor when alone, or a potent one when fused with a heterologous protein containing a KRAB B-domain.

This gene encodes a zinc finger protein containing a Kruppel-associated box (KRAB) A-box domain at its N-terminus, followed by fourteen contiguous C2H2 zinc finger domains and a degenerate zinc finger. The KRAB A-box showed weak transcriptional repressor activity in a reporter gene assay. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 7695 — RefSeq curated summary.

At a glance

Clinical variants (ClinVar): 66 total
MANE Select transcript: NM_003437

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12920
Approved symbol	ZNF136
Name	zinc finger protein 136
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	pHZ-20
Ensembl gene	ENSG00000196646
Ensembl biotype	protein_coding
OMIM	604078
Entrez	7695

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 retained_intron

ENST00000343979, ENST00000418338, ENST00000425827, ENST00000439995, ENST00000464860, ENST00000476676, ENST00000652580, ENST00000892745

RefSeq mRNA: 3 — MANE Select: NM_003437 NM_001348013, NM_001348014, NM_003437

CCDS: CCDS32916, CCDS92526

Canonical transcript exons

ENST00000343979 — 4 exons

Exon	Start	End
ENSE00001416397	12186570	12189871
ENSE00003588758	12186114	12186174
ENSE00003682745	12185785	12185911
ENSE00003850167	12163096	12163206

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 95.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.3233 / max 199.0094, expressed in 1691 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
173985	11.3233	1691

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	95.82	gold quality
oocyte	CL:0000023	93.83	gold quality
calcaneal tendon	UBERON:0003701	91.97	gold quality
tendon	UBERON:0000043	88.46	gold quality
tendon of biceps brachii	UBERON:0008188	86.91	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.46	gold quality
bone marrow	UBERON:0002371	83.42	gold quality
medial globus pallidus	UBERON:0002477	81.83	gold quality
bone marrow cell	CL:0002092	81.75	gold quality
superficial temporal artery	UBERON:0001614	81.74	gold quality
ganglionic eminence	UBERON:0004023	81.18	gold quality
ventricular zone	UBERON:0003053	80.96	gold quality
monocyte	CL:0000576	80.63	gold quality
mononuclear cell	CL:0000842	80.45	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.43	gold quality
leukocyte	CL:0000738	80.36	gold quality
adrenal tissue	UBERON:0018303	80.09	gold quality
mucosa of urinary bladder	UBERON:0001259	80.02	gold quality
islet of Langerhans	UBERON:0000006	79.81	gold quality
nipple	UBERON:0002030	79.70	gold quality
sural nerve	UBERON:0015488	79.65	gold quality
cortical plate	UBERON:0005343	79.58	gold quality
globus pallidus	UBERON:0001875	79.45	gold quality
lymph node	UBERON:0000029	79.25	gold quality
cauda epididymis	UBERON:0004360	79.03	gold quality
left ovary	UBERON:0002119	78.70	gold quality
embryo	UBERON:0000922	78.54	gold quality
endometrium	UBERON:0001295	78.34	gold quality
cranial nerve II	UBERON:0000941	77.94	gold quality
popliteal artery	UBERON:0002250	77.93	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-CURD-10	no	865.04
E-ANND-3	no	4.19

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA1588.1	ZNF136	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:27852650

miRNA regulators (miRDB)

67 targeting ZNF136, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-23A-5P	99.94	65.39	468
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-589-3P	99.91	69.62	2088

Literature-anchored findings (GeneRIF, showing 1)

Through peptide mass fingerprinting, the hepatitis C virus NS2-interacting protein was found to be homologous to a repressor of transcription, ZNF136. (PMID:24136724)

Cross-species orthologs

0 orthologs

Paralogs (51): WIZ (ENSG00000011451), ZNF416 (ENSG00000083817), MYNN (ENSG00000085274), PRDM4 (ENSG00000110851), PRDM2 (ENSG00000116731), ZBTB17 (ENSG00000116809), ZNF644 (ENSG00000122482), GZF1 (ENSG00000125812), ZNF426 (ENSG00000130818), ZNF287 (ENSG00000141040), ZNF697 (ENSG00000143067), ZNF687 (ENSG00000143373), ZNF214 (ENSG00000149050), ZNF547 (ENSG00000152433), ZNF776 (ENSG00000152443), ZNF230 (ENSG00000159882), ZNF222 (ENSG00000159885), ZNF233 (ENSG00000159915), ZNF333 (ENSG00000160961), ZNF319 (ENSG00000166188), ZNF592 (ENSG00000166716), ZNF646 (ENSG00000167395), ZNF507 (ENSG00000168813), ZNF768 (ENSG00000169957), ZNF417 (ENSG00000173480), ZNF408 (ENSG00000175213), ZBTB41 (ENSG00000177888), ZNF223 (ENSG00000178386), ZNF852 (ENSG00000178917), ZNF784 (ENSG00000179922), ZNF572 (ENSG00000180938), ZNF707 (ENSG00000181135), ZNF746 (ENSG00000181220), ZNF467 (ENSG00000181444), ZNF530 (ENSG00000183647), ZNF17 (ENSG00000186272), ZNF527 (ENSG00000189164), ZKSCAN7 (ENSG00000196345), ZNF34 (ENSG00000196378), ZNF774 (ENSG00000196391)

Protein

Protein identifiers

Zinc finger protein 136 — P52737 (reviewed: P52737)

All UniProt accessions (5): A0A494C0J2, C9J2Q9, C9JJK8, C9JR58, P52737

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation as a weak repressor when alone, or a potent one when fused with a heterologous protein containing a KRAB B-domain.

Subcellular location. Nucleus.

Tissue specificity. Seems ubiquitous. Seen in the heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (3): NP_001334942, NP_001334943, NP_003428* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352, PF13894, PF13912

UniProt features (18 total): zinc finger region 14, chain 1, domain 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P52737-F1	74.49	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 191

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway
R-HSA-9843940	Regulation of endogenous retroelements by KRAB-ZFP proteins

MSigDB gene sets: 84 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, MODULE_123, MODULE_98, MILI_PSEUDOPODIA_CHEMOTAXIS_UP, ZHANG_BREAST_CANCER_PROGENITORS_UP, DANG_BOUND_BY_MYC, CHEN_HOXA5_TARGETS_9HR_UP, chr19p13, BENPORATH_MYC_MAX_TARGETS, MATSUDA_NATURAL_KILLER_DIFFERENTIATION, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_DN, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II

GO Biological Process (4): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Regulation of endogenous retroelements	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
negative regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
transition metal ion binding	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

500 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF136	LGALS4	P56470	549
ZNF136	CLHC1	Q8NHS4	419
ZNF136	COMMD5	Q9GZQ3	369
ZNF136	RPS7	P23821	330
ZNF136	ARGFX	A6NJG6	324
ZNF136	DUXA	A6NLW8	280
ZNF136	PRAMEF25	A6NGN4	278
ZNF136	TRIM28	Q13263	265
ZNF136	KRT25	Q7Z3Z0	259
ZNF136	SCLT1	Q96NL6	252
ZNF136	POLR3G	O15318	229
ZNF136	PHC2	Q8IXK0	227
ZNF136	ARID3B	Q8IVW6	226
ZNF136	ZDHHC7	Q9NXF8	225
ZNF136	FOXJ3	Q9UPW0	222

IntAct

55 interactions, top by confidence:

A	B	Type	Score
MDFI	ZNF136	psi-mi:“MI:0915”(physical association)	0.880
ZNF136	MDFI	psi-mi:“MI:0915”(physical association)	0.880
ZNF136	CCNDBP1	psi-mi:“MI:0915”(physical association)	0.740
CCNDBP1	ZNF136	psi-mi:“MI:0915”(physical association)	0.740
CEP70	ZNF136	psi-mi:“MI:0915”(physical association)	0.700
ZNF136	CEP70	psi-mi:“MI:0915”(physical association)	0.700
ZNF136	MTUS2	psi-mi:“MI:0915”(physical association)	0.670
MTUS2	ZNF136	psi-mi:“MI:0915”(physical association)	0.670
	ZNF136	psi-mi:“MI:0915”(physical association)	0.560
ZNF136	STX1A	psi-mi:“MI:0915”(physical association)	0.560
CLK2	ZNF136	psi-mi:“MI:0915”(physical association)	0.560
TRIM28	ZNF136	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (49): ZNF136 (Two-hybrid), MTUS2 (Two-hybrid), CCNDBP1 (Two-hybrid), CEP70 (Two-hybrid), KRTAP10-3 (Two-hybrid), ZNF136 (Two-hybrid), ZNF136 (Two-hybrid), ZNF136 (Two-hybrid), ZNF136 (Two-hybrid), ZNF136 (Affinity Capture-MS), ZNF136 (Affinity Capture-MS), ZNF136 (Two-hybrid), ZNF136 (Two-hybrid), ZNF136 (Two-hybrid), ZNF136 (Two-hybrid)

ESM2 similar proteins: A2RRD8, A6NHJ4, B4DX44, O75346, P10077, P10755, P15621, P16372, P16373, P51786, P52737, P85977, Q0VGE8, Q14588, Q147U1, Q15928, Q15973, Q2M3X9, Q3KNS6, Q3MIS6, Q494X3, Q5HY98, Q5RBQ3, Q5REK1, Q5VIY5, Q60585, Q61751, Q6GQR8, Q7L2R6, Q7TSH9, Q8IYX0, Q8N782, Q8N823, Q8N988, Q8N9F8, Q8NA42, Q8NCK3, Q8NDP4, Q8NEP9, Q8TC21

Diamond homologs: A0JPK3, A8MT65, C9JN71, E9QAG8, G3X9G7, O75820, P16373, P16374, P16415, P17017, P17024, P17025, P51815, P52737, Q08AG5, Q08ER8, Q0D2J5, Q15973, Q2M218, Q3KP31, Q3V080, Q494X3, Q4R4C7, Q5MYW4, Q5R9F0, Q5R9S5, Q5REI6, Q5REK1, Q68EA5, Q6P560, Q6P5C7, Q6ZQV5, Q7L945, Q86T29, Q8BGV5, Q8C6P8, Q8IYI8, Q8IZC7, Q8N7K0, Q8N972

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

390 predictions. Top by Δscore:

Variant	Effect	Δscore
19:12185767:A:AG	acceptor_gain	1.0000
19:12185768:T:G	acceptor_gain	1.0000
19:12185769:ATGT:A	acceptor_gain	1.0000
19:12185769:ATGTG:A	acceptor_gain	1.0000
19:12185770:T:G	acceptor_gain	1.0000
19:12185770:T:TA	acceptor_gain	1.0000
19:12185772:T:TA	acceptor_gain	1.0000
19:12185773:G:A	acceptor_gain	1.0000
19:12185911:GGTAA:G	donor_loss	1.0000
19:12185912:GTA:G	donor_loss	1.0000
19:12185913:T:G	donor_loss	1.0000
19:12186568:A:AG	acceptor_gain	1.0000
19:12186569:G:GG	acceptor_gain	1.0000
19:12186569:GAA:G	acceptor_gain	1.0000
19:12163203:AATG:A	donor_gain	0.9900
19:12163205:TG:T	donor_gain	0.9900
19:12163206:GG:G	donor_gain	0.9900
19:12163207:G:A	donor_loss	0.9900
19:12163207:G:GG	donor_gain	0.9900
19:12163208:T:G	donor_loss	0.9900
19:12185766:C:G	acceptor_gain	0.9900
19:12185767:ATAT:A	acceptor_gain	0.9900
19:12185769:A:AG	acceptor_gain	0.9900
19:12185769:AT:A	acceptor_gain	0.9900
19:12185781:TCA:T	acceptor_loss	0.9900
19:12185782:CA:C	acceptor_loss	0.9900
19:12185783:A:AG	acceptor_gain	0.9900
19:12185783:A:G	acceptor_loss	0.9900
19:12185783:AG:A	acceptor_gain	0.9900
19:12185784:G:GA	acceptor_loss	0.9900

AlphaMissense

3612 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:12187243:T:C	F289L	0.995
19:12187245:C:A	F289L	0.995
19:12187245:C:G	F289L	0.995
19:12187747:T:C	F457L	0.995
19:12187749:C:A	F457L	0.995
19:12187749:C:G	F457L	0.995
19:12187327:T:C	F317L	0.992
19:12187329:C:A	F317L	0.992
19:12187329:C:G	F317L	0.992
19:12187831:T:C	F485L	0.992
19:12187833:T:A	F485L	0.992
19:12187833:T:G	F485L	0.992
19:12187411:T:C	F345L	0.990
19:12187413:T:A	F345L	0.990
19:12187413:T:G	F345L	0.990
19:12187075:T:C	F233L	0.989
19:12187077:C:A	F233L	0.989
19:12187077:C:G	F233L	0.989
19:12187452:C:A	H358Q	0.988
19:12187452:C:G	H358Q	0.988
19:12187284:T:A	H302Q	0.987
19:12187284:T:G	H302Q	0.987
19:12187620:C:A	H414Q	0.987
19:12187620:C:G	H414Q	0.987
19:12186991:T:C	F205L	0.986
19:12186993:T:A	F205L	0.986
19:12186993:T:G	F205L	0.986
19:12187663:T:C	F429L	0.985
19:12187665:C:A	F429L	0.985
19:12187665:C:G	F429L	0.985

dbSNP variants (sampled 300 via entrez): RS1000037954 (19:12168121 G>A), RS1000080695 (19:12182860 A>G), RS1000168874 (19:12181946 T>A), RS1000194418 (19:12169882 C>T), RS1000270804 (19:12168046 C>A,T), RS1000338096 (19:12166271 C>A), RS1000385903 (19:12177898 G>A,C,T), RS1000475834 (19:12188240 C>G), RS1000495542 (19:12171982 T>C), RS1000726243 (19:12177123 A>G), RS1000930960 (19:12176988 C>G), RS1001159537 (19:12181619 C>T), RS1001233623 (19:12170531 G>T), RS1001271056 (19:12167677 T>C), RS1001445076 (19:12166881 G>A,C,T)

Disease associations

OMIM: gene MIM:604078 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	3
sodium arsenite	decreases expression, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	increases expression	1
TAK-243	increases sumoylation	1
propionaldehyde	increases expression	1
terbufos	increases methylation	1
arsenite	affects binding, decreases reaction	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation	1
jinfukang	affects cotreatment, decreases expression	1
prothioconazole	decreases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Air Pollutants, Occupational	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Fonofos	increases methylation	1
Ethyl Methanesulfonate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Nickel	increases expression	1
Parathion	increases methylation	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.